BMO Capital: 'Trevi Therapeutics (TRVI) Stands Alone in RCC Following Nocion Study Failure'

October 7, 2026 9:36 AM

BMO Capital analyst Connor Murphy reiterated an Outperform rating and $36.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found